Physician profile
Victoria Acker
NPI 1366200529
$3,823.07
in general payments reported to CMS, 2019-2025
27 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,670 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,810 · Education: $13.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,809.60 |
| Education | $13.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $550.79 | 2024-2025 | Tepezza, Repatha, Evenity |
| Abbott Laboratories | $350.36 | 2024-2025 | Freestyle Libre 3 |
| Cequr Corporation | $295.72 | 2024-2025 | Cequr Simplicity |
| Lilly USA, LLC | $283.55 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Corcept Therapeutics | $271.80 | 2024-2025 | Korlym |
| Dexcom, INC. | $234.44 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.50 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $215.72 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Sequel Med Tech, LLC | $209.17 | 2024-2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $195.91 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $174.63 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $170.89 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $161.54 | 2024-2025 | Tymlos |
| Insulet Corporation | $86.76 | 2024-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $54.50 | 2024-2025 | Unithroid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $52.70 | 2024 | Veozah |
| Amphastar Pharmaceuticals, INC. | $47.30 | 2024-2025 | |
| Beta Bionics, INC. | $38.23 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $30.40 | 2025 | Strensiq |
| Madrigal Pharmaceuticals | $30.37 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $25.18 | 2025 | |
| Recordati_rare_diseases_inc. | $21.87 | 2025 | Isturisa |
| Rgh Enterprises LLC | $21.01 | 2025 | |
| Rhythm Pharmaceuticals, INC. | $18.59 | 2025 | Imcivree |
| Abbvie INC. | $17.68 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.67 | 2024 | |
| Ascendis Pharma Endocrinology INC | $16.79 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.